Neuropathy News and Research

RSS

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Celgene Corporation announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases.

27 May 2010

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.

26 May 2010

Combination therapy improves patients with depression symptoms: Study

New data presented today at the American Psychiatric Association's annual meeting suggests a benefit to combining L-methylfolate, a prescription medical food called Deplin, with an antidepressant at the start of treatment. This retrospective analysis showed a significantly greater improvement in depression symptoms in a shorter period of time, when patients with Major Depressive Disorder were started on combination therapy.

25 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author of the abstract on the palifosfamide study entitled, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)", will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7th at 2:15 pm in the Vista Room (location S 406).

21 May 2010

The Neuropathy Association joins with the Empire State Building to recognize National Neuropathy Week

For National Neuropathy Week, May 17-21, The Neuropathy Association will join with the Empire State Building to raise neuropathy awareness, recognize National Neuropathy Week, and commemorate the Association's 15th Anniversary.

17 May 2010

Dartmouth College receives $35M to establish The Dartmouth Center for Health Care Delivery Science

Dartmouth College has received a $35 million commitment to establish The Dartmouth Center for Health Care Delivery Science, President Jim Yong Kim announced today. The anonymous gift will advance a new field of study, harnessing the knowledge and expertise of faculty across multiple disciplines from the arts and sciences as well as from the medical, business and engineering schools.

17 May 2010

New Infrared Relief therapy now available for patients with diabetic neuropathies

Genesis Spine Associates now offers Infrared Relief - a new, highly effective pain management therapy using infrared light for patients suffering from diabetic neuropathies. This new therapy offers a simple, painless option for managing patients' pain without potentially dangerous drugs or surgery.

14 May 2010

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

A National Institutes of Health grant will help University of Central Florida researchers explore new ways to potentially reverse the damage caused by multiple sclerosis and other neurological disorders.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

High resolution ultrasound can be used to evaluate patients with foot drop: Study

High resolution ultrasound should be the imaging test of choice when evaluating patients with foot drop (an inability or difficulty in moving the ankle and toes causing uncontrolled slapping of the foot while taking a step), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

7 May 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

Gamma Knife stereotactic radiosurgery effective for patients with large acoustic neuromas: Study

A new Mayo Clinic study has found that Gamma Knife stereotactic radiosurgery is a successful treatment for the majority of patients who have large acoustic neuromas (also known as vestibular schwannoma or neurolemmoma). Gamma Knife surgery already is an accepted treatment for small to medium-sized acoustic neuromas.

5 May 2010

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.

3 May 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

Neuropathy News and Research

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Combination therapy improves patients with depression symptoms: Study

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

The Neuropathy Association joins with the Empire State Building to recognize National Neuropathy Week

Dartmouth College receives $35M to establish The Dartmouth Center for Health Care Delivery Science

New Infrared Relief therapy now available for patients with diabetic neuropathies

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

High resolution ultrasound can be used to evaluate patients with foot drop: Study

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Gamma Knife stereotactic radiosurgery effective for patients with large acoustic neuromas: Study

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News